atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
Book now to reserve your spot and to be at the forefront of safeguarding healthcare data and infrastructure at the Convenzis Group' The Healthcare Cyber Security Conference in June.
Nearly 400 #health and #SocialCare providers across three Integrated Care Systems have collaborated to establish one of the UK’s largest shared care record using InterSystems HealthShare.
The initiative integrates the health and social care data of 3.2 million citizens into a unified record, enhancing…
Attendees
Sponsors and
Exhibitors
Media
Contact us